Melissa Hopple, MD
Family Medicine · Canal Winchester, OHNPI 1841267812
Payments from drug & device makers
Across 174 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$374
- AbbVie$332
- Pfizer$283
- Novo Nordisk$231
- Lilly USA, LLC$220
- Amgen$181
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,97397%
- Education$853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 11 | $374 |
| AbbVie(2 entities) | 18 | $332 |
| Pfizer | 17 | $283 |
| Novo Nordisk | 16 | $231 |
| Lilly USA, LLC | 16 | $220 |
| Amgen(2 entities) | 12 | $181 |
| Merck | 10 | $139 |
| Dexcom, Inc. | 4 | $127 |
| Boehringer Ingelheim | 8 | $124 |
| Novartis | 5 | $103 |
| GSK | 6 | $95 |
| Amarin Pharma, Inc. | 5 | $82 |
| Exact Sciences | 3 | $70 |
| AstraZeneca | 5 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $54 |
| Bayer | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $40 |
| Medtronic | 2 | $35 |
| Shield Therapeutics Inc | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Shire North American Group Inc | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Corium, LLC | 2 | $24 |
| Boston Scientific | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Cranial Technologies, Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$121
How this compares
$3,058 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 92 | $97,250 |
| EliquisApixaban | 69 | $58,127 |
| MounjaroTirzepatide | 40 | $41,406 |
| JanuviaSitagliptin Phosphate | 21 | $30,621 |
| TrulicityDulaglutide | 20 | $29,222 |
| XareltoRivaroxaban | 18 | $23,899 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $23,572 |
| JardianceEmpagliflozin | 24 | $21,932 |
| LinzessLinaclotide | 21 | $15,509 |
| Repatha SureclickEvolocumab | 23 | $14,388 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $14,268 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,636 |
| FarxigaDapagliflozin Propanediol | 22 | $12,254 |
| Spiriva HandihalerTiotropium Bromide | 12 | $10,062 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 24 | $7,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $231 | $97,25092 claims |
| Lilly USA, LLCMounjaro, Trulicity | $220 | $70,62760 claims |
| PfizerEliquis, Abrysvo | $283 | $65,78693 claims |
| MerckJanuvia | $139 | $30,62121 claims |
| Johnson & JohnsonXarelto | $27 | $23,89918 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $95 | $23,52756 claims |
| Boehringer IngelheimJardiance | $124 | $21,93224 claims |
| AbbVieLinzess, Synthroid | $332 | $16,76846 claims |
| AstraZenecaFarxiga | $66 | $12,25422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Canal Winchester
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.